Close Menu

This article has been updated with financial and other details from a Natera regulatory filing.

NEW YORK – Foundation Medicine and Natera said today that they will jointly develop and commercialize personalized circulating tumor DNA monitoring assays for biopharmaceutical and clinical customers who order the FoundationOne CDx test.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.